Literature DB >> 18810227

Acute kidney injury after transarterial chemoembolization for hepatocellular carcinoma: a retrospective analysis.

Jongha Park1, Hyun Chul Chung, Jong Soo Lee, Byeong Man Lee, Dong Min Kim, Jae Cheol Hwang, Min-Woo Jo, Maengseok Noh, Jung Woo Shin.   

Abstract

BACKGROUND: Transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) may result in acute kidney injury (AKI) like other angiographic interventions.
METHODS: To investigate the incidence, risk factor and outcomes of AKI after TACE, defined by Acute Kidney Injury Network (AKIN) criteria, we retrospectively analyzed 442 TACE treatment sessions in 236 HCC patients.
RESULTS: The incidence of AKI in the first 48 h after TACE was 9.8% (23 of 236 patients at risk). Presence of hypertension (OR 3.24, 95% CI 1.21-8.72, p = 0.02), lower baseline serum albumin (OR 0.29, 95% CI 0.15-0.56, p < 0.01) and higher creatinine level (OR 12.02, 95% CI 3.49-41.39, p < 0.01) were independent risk factors of AKI. Prolonged renal insufficiency after 1 month was observed in 24.1% of AKI episodes.
CONCLUSION: AKI is a common complication after TACE and we have to pay attention to the prevention and early recognition of AKI occurrence in high-risk patients. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810227     DOI: 10.1159/000157322

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  7 in total

1.  Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma.

Authors:  Mari Aoe; Takafumi Kanemitsu; Takamasa Ohki; Satoru Kishi; Yoshiyasu Ogura; Yuto Takenaka; Toyohiro Hashiba; Hiroko Ambe; Emi Furukawa; Yu Kurata; Masahiro Ichikawa; Ken Ohara; Tomoko Honda; Satoshi Furuse; Katsunori Saito; Nobuo Toda; Naobumi Mise
Journal:  Clin Exp Nephrol       Date:  2019-06-10       Impact factor: 2.801

2.  Acute Kidney Injury in Adult Patients With Hepatocellular Carcinoma After TACE or Hepatectomy Treatment.

Authors:  Zhixiang Mou; Tianjun Guan; Lan Chen
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

3.  The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC).

Authors:  Katsumi Hayakawa; Masato Tanikake; Toshihiko Kirishima; Naomi Yoshinami; Hiroyuki Shintani; Eiji Yamamoto; Taisuke Morimoto
Journal:  Eur Radiol       Date:  2014-02-13       Impact factor: 5.315

4.  Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Chunze Zhou; Ruifeng Wang; Yikun Ding; Linan Du; Changlong Hou; Dong Lu; Li Hao; Weifu Lv
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

5.  Challenges of transarterial therapy for hepatocellular carcinoma in patients with chronic kidney disease.

Authors:  Wei-Chen Lin; Chen-Wang Chang; Ching-Wei Chang; Tsang-En Wang; Ming-Jen Chen; Horng-Yuan Wang
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

6.  Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) Study.

Authors:  Junhui Sun; Guanhui Zhou; Xiaoxi Xie; Wenjiang Gu; Jing Huang; Dedong Zhu; Wenhao Hu; Qinming Hou; Changsheng Shi; Tiefeng Li; Xin Zhang; Wenbin Ji; Shihong Ying; Zhiyi Peng; Jian Zhou; Zhihai Yu; Jiansong Ji; Haijun Du; Xiaohua Guo; Jian Fang; Jun Han; Huanhai Xu; Zhichao Sun; Wenqiang Yu; Guoliang Shao; Xia Wu; Hongjie Hu; Ling Li; Jiaping Zheng; Jun Luo; Yutang Chen; Guohong Cao; Tingyang Hu
Journal:  Oncol Res       Date:  2019-09-26       Impact factor: 5.574

Review 7.  Hypoalbuminemia and acute kidney injury: a meta-analysis of observational clinical studies.

Authors:  Christian J Wiedermann; Wolfgang Wiedermann; Michael Joannidis
Journal:  Intensive Care Med       Date:  2010-06-02       Impact factor: 17.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.